Survey NEN / Inquérito NEN


  • Carla Andressa Rodrigues Dias Fleury de Lima
  • Renata D'Alpino Peixoto
  • Rui F. Weschenfelder
  • Gabriel Prolla
  • Juliana F Rego
  • Duilio Rocha
  • Marcela Crosara
  • Gustavo Fernandes
  • Paulo M Hoff
  • Aline Chaves Andrade
  • Anelisa K. Coutinho
  • Rachel P. Riechelmann



Neuroendocrine Carcinoma, antineoplastics, surveys and questionnaires, health system.


Introduction: Although new treatments and diagnostic methods for Neuroendocrine Neoplasms (NEN) have been introduced, the level of access to them needs somehow to be further investigated. Objectives: to understand the aspects that influence the access to the diagnosis, follow-up and treatment of patients with NEN in Brazil. Methods: This is a cross-sectional electronic survey conducted by the Brazilian Group of Gastrointestinal Tumors (GTG) and containing sixteen questions sent to Brazilian Oncologists via messaging app, aiming to identify access profiles to diagnostic and follow-up tests among patients with NEN, in addition to proven effective treatments in the Public and Private Brazilian Health Care System. Descriptive analysis was used to report the outcomes.

Results: The survey was carried out with 201 Oncologists. Since (31.8%) of the Oncologists responded that they have been trained for more than 15 years and have been working with clinical practice within the scope of the Brazilian National Health System and/or the Private Health Care. For follow-up, the most requested marker was Chromogranin A (39%). Regarding diagnosis, 35.8% of the 201 participants claim to ask for a slide review in their clinical practice, and their access to tomography and resonance (58%). When contextualizing the performance of PET Scan with Gallium 68, it is available in (15%), but a significant percentage did not have access in the Brazilian National Health System Service, corresponding to (95%). Subgroup analysis revealed statistically significant differences in the availability of Somatostatin Analogue, being offered in 56% in the Brazilian National Health System and 84% in the Private Health Care (p < 0.05). Conclusion: This is the first Brazilian research that evaluated access to diagnostic and therapeutic tools in the Brazilian scenario, showing important access limitations, especially in the public sector. In view of the results presented, these restrictions can lead to unfavorable clinical outcomes in patients with NEN in Brazil.


Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-72.

Laskaratos FM, Caplin M. Treatment challenges in and outside a network setting: Gastrointestinal neuroendocrine tumours. Eur J Surg Oncol. 2019;45(1):52-59.

Cohen L, Manion L. Research methods in education. 4th ed. London: Routledge; 1994.

Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017;19(12):991-1002.

O'Dorisio TM, Harris AG, O'Dorisio MS. Evolution of neuroendocrine tumor therapy. Surg Oncol Clin N Am. 2020;29(2):145-163.

André MEDA. Formação de professores no Brasil (1990-1998). Brasília: MEC/INEP/COMPED; 2002. (Série Estado do Conhecimento, nº 6)

Takano GHS. Perfil imunoistoquímico dos tumores neuroendócrinos. Dissertação (Mestrado em Ciências Médicas) - Universidade de Brasília, Brasília, 2007.

Babbie E. Métodos de pesquisa de survey. Belo Horizonte: Editora UFMG; 2003.

Laville C, Dionne J. A construção do saber: manual de metodologia da pesquisa em ciências humanas. Porto Alegre: ARTMED; 1999.

Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656-63.

Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005-2012.

Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844-860.

Canguçu AL. Avaliação prognóstica da intensidade de achados de tumor budding em pacientes com câncer de cólon de estádio II. [Dissertação]. São Paulo: Fundação Antônio Prudente; 2020.

Janson ET, Westlin JE, Eriksson B, Ahlström H, Nilsson S, Oberg K. [111In-DTPA-D-Phe1] octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol. 1994;131(6):577-81.





Original Papers